Navigation Links
Cyberonics Names Rohan J. Hoare, Ph.D. Senior Vice President, Strategic Planning

HOUSTON, Sept. 12, 2013 /PRNewswire/ -- Cyberonics, Inc. (NASDAQ: CYBX) today announced that Rohan J. Hoare, Ph.D., has joined the company as Senior Vice President, Strategic Planning.  Dr. Hoare will lead business strategy development and execution and functional capability building within Cyberonics.   

Previously, Dr. Hoare was the President of St. Jude Neuromodulation Division, which designs, manufactures and sells neuromodulation devices for the treatment of chronic pain, movement disorders and chronic migraine headache. In his nine years with St. Jude Neuromodulation (formerly Advanced Neuromodulation Systems, Inc.), he held leadership roles in strategy, therapy development and R&D, where he was responsible for developing and launching numerous products and therapies.  He began his career with McKinsey & Co., a premiere strategy consulting firm, where he served clients in high tech, med tech and healthcare payor and providers for nearly a decade.

"We are pleased to welcome Rohan to the Cyberonics management team.  Rohan has many years of experience in the medical device industry and specifically within neuromodulation," said Dan Moore, Cyberonics' President and Chief Executive Officer.  "His experience will be invaluable as we continue to build the company and plan for successful and profitable growth over the long term."

Rohan received a Bachelor of Science in Physics and was awarded Faculty of Science Scholar honors at Monash University, Melbourne, Australia.  He continued his studies at Harvard University as a Fulbright Scholar, where he received a Master of Arts and a Ph.D. in Physics.

About Cyberonics, Inc. and the VNS Therapy® System

Cyberonics, Inc. is a medical technology company with core expertise in neuromodulation.  The company developed and markets the VNS Therapy System, which is FDA-approved for the treatment of refractory epilepsy and treatment-resistant depression.  The VNS Therapy System uses an implanted medical device that delivers pulsed electrical signals to the vagus nerve.  Cyberonics markets the VNS Therapy System in selected markets worldwide.

Additional information on Cyberonics and the VNS Therapy System is available at

Safe harbor statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended.  These statements can be identified by the use of forward-looking terminology, including "may," "believe," "will," "expect," "anticipate," "estimate," "plan," "intend," "forecast," or other similar words.  Statements contained in this press release are based on information presently available to us and assumptions that we believe to be reasonable.  We are not assuming any duty to update this information if those facts change or if we no longer believe the assumptions to be reasonable. Investors are cautioned that all such statements involve risks and uncertainties, including without limitation, statements concerning building the company and achieving profitable growth over the long term.  Our actual results may differ materially.  Important factors that may cause actual results to differ include, but are not limited to: continued market acceptance of VNS Therapy and sales of our products; the development and satisfactory completion of clinical trials and/or market test and/or regulatory approval of new products, including VNS Therapy for the treatment of other indications; satisfactory completion of the post-market registry required by the U.S. Food and Drug Administration as a condition of approval for the treatment-resistant depression indication; adverse changes in coverage or reimbursement amounts by third-parties; intellectual property protection and potential infringement claims; maintaining compliance with government regulations and obtaining necessary government approvals for new products and indications; product liability claims and potential litigation; reliance on single suppliers and manufacturers for certain components; the accuracy of management's estimates of future expenses and sales; the potential identification of material weaknesses in our internal controls over financial reporting; and other risks detailed from time to time in our filings with the Securities and Exchange Commission (SEC).  For a detailed discussion of these and other cautionary statements, please refer to our most recent filings with the SEC, including our Annual Report on Form 10-K for the fiscal year ended April 26, 2013 and our Quarterly Report on Form 10-Q for the fiscal quarter ended July 26, 2013.

Contact Information

Greg Browne, CFO
Cyberonics, Inc.
100 Cyberonics Blvd.
Houston, TX 77058
Main:  (281) 228-7262 
Fax:  (281) 218-9332

SOURCE Cyberonics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cyberonics To Report Fiscal Year 2014 First Quarter Results And Host Webcast And Conference Call On August 22, 2013
2. Cyberonics To Report Fourth Quarter And Fiscal Year 2013 Results And Host Webcast And Conference Call On June 5, 2013
3. Cyberonics to Participate in Upcoming Investor Conferences
4. Cyberonics Announces Update On Hagerty Lawsuit
5. Free Research Report on Laboratory Corp. of America Holdings, Sony Corp., Cyberonics, Inc., Olin Corp. and Deluxe Corp.
6. Cyberonics To Present At The 24th Annual Piper Jaffray Healthcare Conference
7. Cyberonics To Report Fiscal Year 2013 Second Quarter Results And Host Webcast And Conference Call On November 16, 2012
8. Cyberonics Announces Investment In cerbomed GmbH
9. Cyberonics To Participate In Upcoming September Investor Conferences
10. Cyberonics To Present At Morgan Stanley 2012 Global Healthcare Conference
11. Cyberonics To Report Fiscal Year 2013 First Quarter Results And Host Conference Call On August 28, 2012
Post Your Comments:
(Date:11/27/2015)... 26, 2015 ... the "2016 Global Tumor Marker Testing ... and Sales Segment Forecasts, Innovative Technologies, Instrumentation ... to their offering. --> ... "2016 Global Tumor Marker Testing Market: ...
(Date:11/26/2015)... November 26, 2015 Un nuevo ... Bremachlorin para el cáncer avanzado.   --> ... terapia fotodinámica de Bremachlorin para el cáncer avanzado. ... la inmunoterapia con la terapia fotodinámica de Bremachlorin para ... Research . --> Clinical Cancer Research . ...
(Date:11/26/2015)... 26, 2015 --> ... approach blends immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer. ... blends immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer. ... blends immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer. ... found that immunotherapy can be efficiently combined with photodynamic ...
Breaking Medicine Technology:
(Date:11/27/2015)... , ... November 27, 2015 , ... ... the health care in America. As people age, more care is needed, especially ... are rising, and medical professionals are being overworked. The forgotten part of this ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... the November 27th edition of USA Today in Atlanta, Dallas, New York, Minneapolis, ... of 750,000. The digital component is distributed nationally, through a vast social media ...
(Date:11/27/2015)... ... 27, 2015 , ... A simply groundbreaking television series, "Voices in America", which ... into an array of issues that are presently affecting Americans. Dedicated to providing the ... show is changing the subjects consumers focus on, one episode at a time. ...
(Date:11/27/2015)... CA (PRWEB) , ... November 27, 2015 , ... ... California Medical Associates, Inc. and Dr. Tucker Bierbaum with Emergency Medicine at ... They observed that both STEMI and Sepsis conditions present in similar ways and require ...
(Date:11/26/2015)... ON (PRWEB) , ... November 26, 2015 , ... ... of a real-time eReferral system for diagnostic imaging in the Waterloo region. Using ... BMD and Nuclear Medicine tests directly from their electronic medical record (EMR) without ...
Breaking Medicine News(10 mins):